We have updated our Terms of Use.
Please read our new Privacy Statement before continuing.

Health check

6 September 2016 By Sara Silver

Fresh from splitting off its industrial arm, the healthcare giant is buying molecular tester Cepheid. Cost cuts cover barely half the 54 pct premium and investors aren’t buying promises of extra revenue. CEO Tom Joyce’s claims of greater efficiency and growth are falling flat.

This content is for Subscribers only

 

Email a friend

Please complete the form below.

Required fields *

*
*
*

(Separate multiple email addresses with commas)